12 Recruiting Breast Neoplasms Phase 3 Clinical Trials
Active phase 3 studies for breast neoplasms enrolling across the USA. Verify eligibility and contact site coordinators.
All Breast Neoplasms studiesPhase 3 Studies for Breast Neoplasms
Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy for HR+/HER2- Locally Recurrent Inoperable or Metastatic Breast Cancer (MK-3475-B49/KEYNOTE-B49)
📍 University of Alabama at Birmingham-Medicine ( Site 0065) — Birmingham, Alabama
View Study & Checklist ➔Trastuzumab Deruxtecan (T-DXd) Alone or in Sequence With THP, Versus Standard Treatment (ddAC-THP), in HER2-positive Early Breast Cancer
📍 Research Site — Springdale, Arkansas
View Study & Checklist ➔Hypofractionated LocoRegional Radiotherapy in Breast Cancer
📍 Tom Baker Cancer Centre — Calgary, Alberta
View Study & Checklist ➔A Study of Abemaciclib (LY2835219) Combined With Fulvestrant in Women With Hormone Receptor Positive HER2 Negative Breast Cancer
📍 St. Bernards Medical Center — Jonesboro, Arkansas
View Study & Checklist ➔A Study of Imlunestrant, Investigator's Choice of Endocrine Therapy, and Imlunestrant Plus Abemaciclib in Participants With ER+, HER2- Advanced Breast Cancer
📍 Ironwood Cancer & Research Centers — Chandler, Arizona
View Study & Checklist ➔A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer
📍 USO - Southern Cancer Center — Daphne, Alabama
View Study & Checklist ➔A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)
📍 Banner MD Anderson Cancer Center ( Site 0066) — Gilbert, Arizona
View Study & Checklist ➔A Clinical Study of Patritumab Deruxtecan to Treat Breast Cancer (MK-1022-016)
📍 Southern Cancer Center (SCC) ( Site 8000) — Daphne, Alabama
View Study & Checklist ➔ROSETTA Breast-01: The Effects and Safety of Pumitamig in Patients With Triple-Negative Breast Cancer
📍 Highlands Oncology Group — Springdale, Arkansas
View Study & Checklist ➔A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)
📍 Alaska Oncology and Hematology — Anchorage, Alaska
View Study & Checklist ➔A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010)
📍 Ironwood Cancer & Research Centers ( Site 0066) — Chandler, Arizona
View Study & Checklist ➔A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)
📍 Local Institution - 0303 — Hot Springs, Arkansas
View Study & Checklist ➔